CPM-LAD


CPM-LAD, or CYPM-LAD, also known as 6--6-nor-LSD, is a serotonin receptor modulator and putative psychedelic drug of the lysergamide family. It is the analogue of LSD in which the methyl group at the 6 position has been replaced with a cyclopropylmethyl group.

Use and effects

Unlike related lysergamides, CPM-LAD was not mentioned in Alexander Shulgin's 1997 book TiHKAL and is not known to have been tested in humans.

Pharmacology

Pharmacodynamics

CPM-LAD showed affinity values for serotonin receptors of 10.9nM for serotonin-labeled 5-HT1 receptors and 7.7nM for ketanserin-labeled 5-HT2 receptors. These affinities were very similar to but slightly lower than those of LSD. CPM-LAD fully substituted for LSD in rodent drug discrimination tests with an of 0.067μmol/kg, relative to a dose of 0.046μmol/kg in the case of LSD. Additional pharmacology for CPM-LAD has also been published.

History

CPM-LAD was first described in the scientific literature by Andrew Joseph Hoffman of the lab of David E. Nichols at Purdue University in 1987. Subsequently, it was patented by Gilgamesh Pharmaceuticals in 2022, who further studied and described its pharmacology. Derivatives of CPM-LAD have also been patented by Daniel Trachsel and Matthias Liechti and colleagues in association with MindMed.

Society and culture

Legal status

Canada

CPM-LAD is not a controlled substance in Canada as of 2025.